LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
Podcasts & Webcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
BioCentury-BayHelix China Healthcare Summit
East-West Healthcare Reception
BioCentury-BayHelix East-West Summit
Bio€quity Europe
BioCentury Grand Rounds Inquiry
The BioCentury Show
Webinars - Upcoming & On-Demand
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Astria Therapeutics Inc.
Headquarters:
Boston, MA, United States of America
Website:
https://astriatx.com/
Year Founded:
2008
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Jill C. Milne, PhD
Number Of Employees:
59
Enterprise Value:
$80,307,100
PE Ratio:
-3.58
Exchange/Ticker 1:
NASDAQ:ATXS
Exchange/Ticker 2:
N/A
Latest Market Cap:
$422,692,192
BioCentury
|
Feb 2, 2024
Finance
Public equity roundup: Alto, Fractyl price IPOs, Vaxcyte raises $750M
Plus: Kyverna lining up a listing next week, and PIPEs for Tectonic, Tyra and Arcus
Read More
BioCentury
|
Nov 7, 2023
Data Byte
October marks year’s third-biggest month for biotech follow-ons
The group’s median market cap performance was positive
Read More
BioCentury
|
Oct 14, 2023
Finance
Oct. 13 Quick Takes: Pfizer trims guidance, cutting costs by $3.5B due to COVID product sales
Plus: FDA approves Pfizer’s ulcerative colitis therapy from Arena deal and updates from Lilly, Novo, Harmony and more
Read More
BioCentury
|
Jul 18, 2023
Management Tracks
Ballinger at the helm at Lyndra
Plus: Bryan Stuart to lead Atavistik and updates from EnteroBiotix, PTC, CureVac, CytomX, ProKidney and more
Read More
BioCentury
|
Apr 19, 2023
Management Tracks
Astria promotes Matthews to CBO
Plus Engimmune hires Nieba as CEO and an update from Cardurion
Read More
BioCentury
|
Dec 16, 2022
Finance
Dec. 15 Quick Takes: Enlaza debuts with $61M, covalent targeting biologics platform
Plus: MinervaX taking strep vaccine to Phase II and updates from AbbVie, Prothena, Astria, Guardant and more
Read More
Items per page:
10
1 - 6 of 6
Help Center
Username
Request a Demo
Request Training
Ask a Question
Elevio by Dixa
Help